Segment Data (Tables)

3 Months Ended

Mar. 29, 2024

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:


	Successor		Predecessor
	Three Months Ended March 29, 2024		Three Months Ended March 31, 2023
Net sales:
Specialty Brands	$	257.3	$	252.0
Specialty Generics	210.5		172.6
Net sales	$	467.8	$	424.6
Operating income (loss):
Specialty Brands	$	29.9	$	32.4
Specialty Generics	38.2		32.8
Segment operating income	68.1		65.2
Unallocated amounts:
Corporate and unallocated expenses (1)	(31.9)		(14.0)
Depreciation and amortization	(35.1)		(145.1)
Share-based compensation	(1.9)		(2.6)
Restructuring charges, net	(10.2)		(1.2)

Liabilities management and separation costs (2)	(6.7)		(4.9)

Operating loss	(17.7)		(102.6)
Interest expense	(59.1)		(162.0)
Interest income	6.8		4.7
Other income (expense), net	3.7		(14.6)
Reorganization items, net (3)	—		(5.6)
Loss from continuing operations before income taxes	$	(66.3)	$	(280.1)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in SG&A, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence from the 2023 Bankruptcy Proceedings and the Company’s emergence from the Chapter 11 cases and Irish examinership proceedings in 2022.

(3)As of December 30, 2023, professional fees directly related to the 2023 Bankruptcy Proceedings that were previously reflected as reorganization items, net, are being classified on a go-forward basis within SG&A expenses.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:


	Successor		Predecessor
	Three Months Ended March 29, 2024		Three Months Ended March 31, 2023
Acthar Gel	$	102.8	$	82.0
INOmax	70.2		82.7
Therakos	58.2		58.7
Amitiza	19.4		24.5
Terlivaz	6.0		2.2
Other	0.7		1.9
Specialty Brands	257.3		252.0

Opioids	81.9		62.2
ADHD	31.7		22.4
Addiction treatment	15.4		15.6
Other	1.5		1.8
Generics	130.5		102.0
Controlled substances	22.9		18.5
APAP	51.7		46.4
Other	5.4		5.7
API	80.0		70.6
Specialty Generics	210.5		172.6
Net sales	$	467.8	$	424.6